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H I G H L I G H T S
 Skin is a target site of As+3 toxicity.
 Metallothionein-3 (MT3) is highly expressed in human skin.
 Skin-derived malignancies also expressed MT3.
 Suggested that MT3 is a major sulfhydryl source for dermal As+3 binding.
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A B S T R A C T
Human skin is a well known target site of inorganic arsenic with effects ranging from hyperkeratosis to
dermal malignancies. The current study characterizes the expression of a protein known to bind
inorganic, As3+, metallothionein 3 (MT-3). Expression of this protein was assessed immunohistochemi-
cally with a speciﬁc MT-3 antibody on human formalin-ﬁxed, parafﬁn-embedded biopsy specimens in
normal skin, squamous cell carcinoma (SCC), basal cell carcinoma (BCC) and melanoma. Assessment in
normal skin using nine normal specimens showed moderate to intense MT-3 staining in epidermal
karatinocytes with staining extending into the basal cells and moderate to intense staining in
melanocytes of nevi. MT-3 immunoexpression was shown to be moderate to intense in 12 of 13 of SCC,
low to moderate in 8 of 10 BCC, and moderate to intense in 12 melanoma samples. MT-3 expression in cell
culture models (normal human epidermal keratinocytes, normal human melanocytes, and HaCaT cells)
showed only trace expression of MT-3, while exposures to the histone deacytalase inhibitor, MS-275,
partially restored expression levels. These results indicate that the epidermis of human skin and resulting
malignancies express high level of MT-3 and potentially impact on the known association of arsenic
exposure and the development of skin disorders and related cancers.
ã 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Inorganic arsenic is a potent human carcinogen, and skin is
known to be one of the most susceptible human organs affected by
chronic environmental exposure to this metalloid (Bolt, 2012).
Chronic arsenic exposure causes a dry skin phenotype characterized
by melanosis, hyperplasia and hyperkeratosis (Komissarova and* Corresponding author. Tel.: +701 777 2561; fax: 701 777 3108.
E-mail addresses: andrea.slusser@med.und.edu (A. Slusser),
yun.zheng@med.und.edu (Y. Zheng), xudong.zhou@med.und.edu (X.D. Zhou),
seema.somji@med.und.edu (S. Somji), donald.sens@med.und.edu (D.A. Sens),
http://dx.doi.org/10.1016/j.toxlet.2014.09.028
0378-4274/ã 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access a
nd/3.0/).Rossman, 2010). The most common arsenic-induced skin cancers
include Bowen's disease (BD, SCC in situ), squamous cell carcinoma
(SCC), and basal cell carcinoma (BCC) (Yeh et al., 1968). There is less
evidence for a potential contribution of arsenic exposure to the
development of melanoma. However, there is emerging evidence
for such an association, especially for melanomas that might arise
from co-exposure to ultraviolet radiation (Cooper et al., 2014;
Pearce et al., 2012; Dennis et al., 2010). Cell culture models have seen
frequent use to investigate the mechanisms involved in arsenic-
induced toxicity and cancer development due to the lack of valid
animal models. These studies have lead to several theories to
explain the carcinogenic effects of arsenic exposure and include the
generation of reactive oxygen species (ROS), oxidative DNA damage,
genomic instability, aneuploidy, gene ampliﬁcation, inhibition ofrticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
142 A. Slusser et al. / Toxicology Letters 232 (2015) 141–148DNA repair, and epigenetic dysregulation (Ren et al., 2011; Straif
et al., 2009; Lee et al., 2012).
This laboratory is interested in how the metallothionein (MT)
gene family might participate in the above processes that are
associated with arsenic-induced carcinogenesis. A role for this
family of proteins might be expected since all MT family members
can bind and sequester 6 atoms of As+3 and can also serve as an
antioxidant (Vasak and Meloni, 2011; Irvine et al., 2013; Garla et al.,
2013). In humans, there are four MT isoforms, designated MT-
1 through MT-4. The MT-1 and MT-2 isoforms have been the
subject of extensive study over the last 50 years and the subject of
numerous reviews (see Vasak and Meloni, 2011). The MT-1 and
MT-2 isoforms are inducible in almost all tissues by a variety of
stress conditions and compounds including glucocorticoids,
cytokines, ROS, and metal ions. In contrast, the identiﬁcation of
the MT-3 and MT-4 isoforms is relatively recent (1990s) and both
isoforms are largely unresponsive to the above inducers and their
expression believed to be conﬁned to far fewer tissue types. The
four MT isoforms share a high degree of sequence homology and a
speciﬁc antibody cannot be produced that can separately identify
the MT-1, 2 and 4 isoforms. The MT-3 isoform is unique in that it
possesses 7 additional amino acids that are not present in any
other member of the MT gene family, a 6 amino acid C-terminal
sequence and a Thr in the N-terminal region (Palmiter et al., 1992;
Tsuji et al., 1992; Uchida et al., 1991). An MT-3 speciﬁc antibody can
be generated against the C-terminal sequence (Garrett et al., 1999).
Functionally, MT-3 has also been shown to possess several
activities not shared by the other MT isoforms. These include a
neuronal cell growth inhibitory activity (Uchida et al., 1991), the
participation in the regulation of EMT in human proximal tubule
cells (Kim et al., 2002; Kim et al., 2002), and the ability to inﬂuence
the choice between apoptotic and necrotic cell death in proximal
tubule cells exposed to cadmium (Somji et al., 2004). This non-
duplication of function occurs despite a 63–69% homology in
amino acid sequence among MT-3 and the other human MT
isoforms (Sewell et al., 1995). These unique features of MT-3, along
with its ability to bind and sequester As+3, motivated the present
study designed to examine the expression of MT-3 in human skin
and related skin cancers. A related question was to determine if
human cell culture models used to study As+3 effects on skin
faithfully recapitulate the in situ expression of MT-3.
2. Materials and methods
2.1. Specimens of human skin
Specimens of normal human skin and associated cancers were
obtained from archival parafﬁn blocks 10 years post diagnosis and
scheduled for disposal as medical waste. These archival specimens
contained no patient identiﬁers and are in the exempt category for
human research. Tissues within these parafﬁn blocks were
routinely ﬁxed in 10% neutral buffered formalin for 16–18 h. The
tissues were transferred to 70% ethanol and dehydrated in 100%
ethanol. Dehydrated tissues were cleared in xylene, inﬁltrated, and
embedded in parafﬁn. Tissue sections were cut at 3–5 mm for use in
routine histology and immunohistochemical protocols.
2.2. Immunostaining for MT-3 in human skin and associated cancers
Serial sections were cut at 3–5 mm for use in immunohisto-
chemical protocols. Staining was performed by a Leica Bond–Max
automatic immunostainer. Major reagents for this procedure were
contained in the Bond Polymer Reﬁne Detection kit (Leica,
DS9800). Parafﬁn sections were processed in the machine from
deparafﬁnization to counterstaining by hematoxyline according to
the manufacturer’s recommended program settings with thefollowing modiﬁcations. Brieﬂy, the major steps in the protocol
include deparafﬁnization, antigen retrieval for 20 min in Bond
Epitope Retrieval Solution 1 (Leica, Catalog No AR9961), peroxide
block for 5 min, incubation with rabbit anti-MT-3 antibody (1:200)
for 25 min at room temperature, incubation with Post Primary for
10 min (source of the anti-rabbit IgG antibody), incubation with
Polymer (source of the anti-rabbit Poly-HRP antibody) for 10 min,
visualization with DAB (diaminobenzidine substrate for color
development) for 10 min, counterstaining with hematoxylin for
5 min. Slides were rinsed in distilled water, dehydrated in graded
ethanol, cleared in xylene, and coverslipped.The presence and
degree of MT-3 immunoreactivity in the specimens was judged by
two pathologists. The scale used was 0 to +3 with 0 indicating no
staining, +1 staining of mild intensity, +2 staining of moderate
intensity, and +3 staining of strong intensity.
2.3. Cell culture
The HaCaT cell line was obtained from Cell Line Services
(Eppelheim, Germany). HaCaT were initially isolated from normal
skin of a 62 year old Caucasian male donor and spontaneously
immortalized through p53 mutation; they are nontumorigenic in
vivo (Boukamp et al., 1988). The cells were maintained in
Dulbecco’s Modiﬁed Eagles Medium (DMEM) supplemented with
4.5 g/L glucose, 2 mM L-glutamine, 10% v/v fetal bovine serum
(FBS), 0.25 mg/mL fungizone, 100 U/mL penicillin and 100 mg/mL
streptomycin. HaCaT cells were given fresh medium every 72 h and
subcultured at a ratio of 1:5. Normal human epidermal keratino-
cyte (NHEK) primary cells were obtained from Lonza (Walkersville,
MD). NHEK were isolated from a 68 year old Caucasian male donor.
The cells were maintained in KBM-Gold (Lonza, Walkersville, MD)
supplemented with KGM-GoldTM–BulletKitTM (Lonza, #
00192060). NHEK were seeded at a density of 3500 cells/cm2
and given fresh media the day after seeding and then every 48 h
until reaching 70–80% conﬂuency. The human epidermal melano-
cyte primary cells isolated from a light pigmented donor were
obtained from Gibco (HEMa-LP) (Carlsbad, CA), and are referred to
as normal human melanocytes (NHM). NHM cells were maintained
in Medium 254 supplemented with PMA-free Human Melanocyte
Growth Supplement-2 (HMGS-2, Gibco, # S-016–5) 0.25 mg/mL
fungizone, 100 U/mL penicillin and 100 mg/mL streptomycin. The
cells were seeded at a density of 5000 cells/cm2 and given fresh
media the day after seeding and then every 48 h until reaching 80%
conﬂuency.
2.4. Treatment of cultured cells with 5-Aza-20-deoxycytidine and
histone deacetylase inhibitor MS-275
HaCaT, NHEK and Primary Melanocytes were seeded at a
1:10 ratio and the next day they were treated with 1 or 3 mM 5-
Aza-20-deoxycytidine (5-AZC) (Sigma–Aldrich, St. Louis, MO) or 1,
3 or 10 mM MS-275 (ALEXIS Biochemicals, Lausen, Switzerland).
The cells were allowed to grow to conﬂuency and then harvested
for RNA isolation.
2.5. RNA Isolation and RT–PCR analysis
Total RNA was isolated from the cells according to the protocol
supplied with TRI REAGENT (Molecular Research Center, Inc.
Cincinnati, OH) as described previously by this laboratory (Somji
et al., 2006). Real time RT–PCR was used to measure the expression
level of MT-3 mRNA utilizing a previously described MT-3 isoform-
speciﬁc primer (Somji et al., 2006). For analysis,1 mg was subjected
to complementary DNA (cDNA) synthesis using the iScript cDNA
synthesis kit (Bio-Rad Laboratories, Hercules, CA) in a total volume
of 20 ml. Real-time PCR was performed utilizing the SYBR Green kit
Table 1
Immunostaining of MT-3 in normal skin, SCCa, BCCb, Nevi, and Melanoma.
Sample # Diagnosis Intensityc Percentaged Commentse
T06–02611 Normal skin 2–3+
T06–04747 Normal skin 2+
T06–08104 Normal skin 2–3+
T06–12296 Normal skin 2–3+
T06–13822 Normal skin 2–3+
T06–15093 Normal skin 1–2+
T06–15738 Normal skin 2–3+
T06–16832 Normal skin 1–2+
T06–17515 Normal skin 1–2+
T06–05920-2 SCC 3+ 90 Normal skin 2+
T06–08560-1 SCC 2–3+ 80 Normal skin 2+
T06–10237-1 SCC 1+ 60 Normal skin 1–2+
T06–17492-3 SCC 2+ 80 Normal skin 2+
T06–18288 SCC 2–3+ 90 No normal skin
T06–19042-2 SCC 2+ 80 No normal skin
T07–02859-3 SCC 2–3+ 70 Normal skin 2+
T07–04441-1 SCC 2+ 60 Normal skin 2–3+
T07–05223-3 SCC 2+ 80 Normal skin 1+
T07–07073-2 SCC 1–2+ 30 No normal skin
T08–11243 SCC 2+ 60 Normal skin 2+
T09–09643-1 SCC 2–3+ 80 Normal skin 2+
T06–13947-1 SCC, in situ 2+ 80 No normal skin
T06–00002 BCC 0–1+ 30 Normal skin 1–2+
T06–03724-2 BCC 1+ 60 No skin
T06–06686-8 BCC 0–1+ 80 Normal skin 1–2+
T06–06889 BCC 1–2+ 80 Normal skin 2+
T06–07160-2 BCC 0–1+ 40 Normal skin 2+
T06–08133-2 BCC NEG 0 Normal skin 1–2+
T06–09327-1 BCC 1+ 60 Normal skin 1–2+
T06–10671-1 BCC 1+ 40 Normal skin 1–2+
T07–00753-2 BCC NEG 0 No normal skin
T07–07197-3 BCC 1–2+ 60 Normal skin 1–2+
T06–05434 Nevus 2–3+ 80
T06–13829 Nevus 2–3+ 80
T06–15352 Nevus 2–3+ 80
T06–16045 Nevus 2–3+ 80
T06–16174 Nevus 2–3+ 80
T06–16832 Nevus 2–3+ 80
T06–16983 Nevus 2+ 80
T06–18076 Nevus 2+ 80
T06–18753 Nevus 2–3+ 80
T06–17364 Nysplastic
nevus
2–3+ 80
T06–02621 in situ
melanoma
2–3+ 80
T06–09160 in situ
melanoma
2–3+ 80
T06–11933 in situ
melanoma
2–3+ 80
T06–08497 Nuperﬁcial
spreading
melanoma
2–3+ 80
T06–11336 Superﬁcial
spreading
melanoma
2–3+ 80
T06–11854 Superﬁcial
spreading
melanoma
2–3+ 80
T06–17070 Superﬁcial
spreading
melanoma
2–3+ 80
T06–02282 Deeply invasive
melanoma
2–3+ 80
T06–03697 Deeply invasive
melanoma
2–3+ 80
T06–05435 Deeply invasive
melanoma
2–3+ 80
T06–07039 Deeply invasive
melanoma
2–3+ 80
T06–16580 Deeply invasive
melanoma
2+ 80
a: Squamous Cell Carcinoma, b: Basal Cell Carcinoma,c: Intensity, scored by a
pathologist see Materials and methods, d: Percentage of the microscopic ﬁeld that
exhibits staining, e: description of the staining within the normal skin component
of the sample.
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volume of 20 ml in an iCycler iQ real-time detection system (Bio-
Rad Laboratories). Ampliﬁcation was monitored by SYBR Green
ﬂuorescence and compared to that of a standard curve of the MT-
3 isoform gene cloned into pcDNA3.1/hygro (+) and linearized with
Fsp I. Cycling parameters consisted of denaturation at 95 C for 30 s
and annealing at 65 C for 45 s which gave optimal ampliﬁcation
efﬁciency of each standard. The level of MT-3 expression was
normalized to that of b-actin assessed by the same assay with the
primer sequences being sense, CGACAACGGCTCCGGCATGT, and
antisense, TGCCGTGCTCGATGGGGTACT, with the cycling param-
eters of annealing/extension at 62 C for 45 s and denaturation at
95 C for 15 s.
3. Results
3.1. MT-3 expression in human skin and related cancers
The expression of MT-3 was determined in normal human skin,
in situ squamous cell carcinoma, squamous cell carcinoma, basal
cell carcinoma, nevus, dysplastic nevus, in situ melanoma,
superﬁcial spreading melanoma, and deeply invasive melanoma
(Table 1). Nine independent specimens of human skin were
evaluated for the expression of MT-3. All nine specimens displayed
immunoreactivity for MT-3 in the epidermis. For each specimen,
the immunoreactivity for MT-3 was uniform throughout the
epidermis and included staining of the basal keratinocytes (Fig 1A).
Six of the specimens exhibited moderate to strong staining for MT-
3 while the other 3 displayed mild to strong intensity of staining
(Table 1). All squamous cell carcinomas (SCC) exhibited staining for
MT-3 (Table 1), ﬁve strongly (Fig 1C), six moderately (Fig 1E), and
one mild to moderate, whereas many of the basal cell carcinomas
(BCC) exhibited low staining (Table 1) with two being totally
devoid of MT-3 expression (Fig 2F), three weakly, and the rest (ﬁve
samples) were either mild or mild to moderate (Fig 1D) in MT-
3 staining. The staining of MT-3 was determined on 9 specimens of
nevus. Staining for MT-3 was found for all 9 specimens, exhibited
moderate to strong intensity, and was present in over 80% of the
cells comprising the nevus (Table 1,Fig 2A). Staining of MT-3 was
also performed on 1 case of dysplastic nevus and 3 cases of in situ
melanoma. The staining was similar to that found in the nevus with
all specimens displaying moderate to strong staining in over 80% of
the cells (Table 1, Fig 2B). Staining of MT-3 was also performed on
4 cases of superﬁcial spreading melanoma and 5 cases of deeply
invasive melanoma. Again, the staining was similar to that found
for in situ melanoma with moderate to strong staining of MT-3 in
over 80% of the melanoma cells (Table 1, Fig 2C, D, E).
3.2. MT-3 expression in primary normal human keratinocytes (NHEK)
and immortalized human HaCat keratinocytes
Proliferating and conﬂuent cultures of NHEK and HaCaT cells
were assessed for their expression of MT-3 mRNA and protein. Real
time PCR demonstrated that both resting and dividing NHEK and
HaCaT cells had only background levels of MT-3 mRNA expression
(Fig 3A, B). Both sets of cells were also shown to express only
background levels of MT-3 protein (data not shown). Both the
NHEK and HaCaT cells were treated with MS-275, a histone
deacetylase inhibitor, and 5-aza-20-deoxycytidine, a DNA methyl-
ation inhibitor, to determine if MT-3 expression might be silenced
by a mechanism involving histone modiﬁcation or DNA methyla-
tion. The results demonstrated that treatment with MS-275 was
effective in restoring MT-3 mRNA expression in both the NHEK and
HaCaT cells (Fig 3A,B). While MS-275 treatment was effective in
both cell lines, MS-275 increased MT-3 mRNA levels in NHEK cells
10 to 20 fold greater than those of the HaCaT cell line. Treatment of
Fig. 1. Immunostaining of MT-3 in Skin Pigment Lesions. A: normal skin shows mild to moderate staining of MT in epidermis (#). In some cases the staining of MT-3 in
epidermis can be moderate to strong (not shown); B: normal kidney as positive control; C: squamous cell carcinoma (SCC) (T06–5920) with strong staining of MT-3 (3 + ); D:
normal skin from the same slide in “C”, showing moderate positivity of MT-3 (2 + ); E: SCC (T07–4411) with mild staining of MT-3 (2 + ); F: normal skin from the same slide as
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Fig. 2. Immunostaining of MT-3 in Nevi and Melanoma Cells. A: in this intradermal nevus, the neval cells, which located in the dermis, show moderate to strong expression of
MT-3 (*). The epidermis at the top of the image is moderately positive for MT-3 (#); B: in this case of in situ melanoma, two nests of melanoma cells in the epidermis are
moderately to strongly positive for MT-3 (*). The epidermis is moderately positive for MT-3 (#); C: in this superﬁcial spreading melanoma, some melanoma nests, located in
the superﬁcial dermis, show strong staining of MT-3. The overlying epidermis is mildly positive for MT-3 (#); D: in this deeply invasive melanoma, the tumor cells are strongly
positive for MT-3 (*). In the top-left corner is a small section of epidermis (#), which is mildly positive for MT-3 (#); E: another case of deeply invasive melanoma. In the center
of this image is a hair follicle (+) with two keratin pearls (arrows) in it. The hair follicle shows moderate staining of MT-3. Around the follicle are nests of invasive melanoma
cell (*), which show strong staining of MT-3. F: BCC (T06–8133) with negative staining of MT-3.
A. Slusser et al. / Toxicology Letters 232 (2015) 141–148 145the NHEK and HaCaT cells with 5-aza-20-deoxycytidine, resulted in
a small, but statistically insigniﬁcant increase in MT-3 mRNA
expression for both cell types (Fig 3A, B).
3.3. MT-3 expression in normal human melanocytes (NHM)
Normal human melanocytes (from a light pigmented donor)
were assessed in proliferating and conﬂuent cultures for expres-
sion of MT-3 mRNA and protein. Both cell cultures showed onlyshown in “E”, showing moderate staining of MT-3 (2 + ); G: SCC (T06–10237) with mild sta
staining of MT-3 (0–1 + ); I: Normal skin from the same slide as shown in “H”, showing 
staining of MT-3 (1–2 + ). All images taken at 200X magniﬁcation.background levels of mRNA as demonstrated with real-time PCR
(Fig 4) and only background levels of protein (data not shown). In
order to test for epigenetic regulation, cultures were treated with
the histone deacetylase inhibitor, MS-275 and the DNA methyla-
tion inhibitor, 5-aza-20-doxycytidine. The results demonstrated
that treatment with MS-275 was effective in restoring MT-3 mRNA
expression in the NHM cells (Fig 4). Treatment of the NHM with 5-
Aza-20-deoxycytidine, resulted in only a slight but statistically
signiﬁcant increase in MT-3 mRNA expression (Fig 4).ining of MT-3 (1 + ); H: basal cell carcinoma (BCC) (T06–00002) with focal, very weak
mild to moderate staining of MT-3 (1–2 + ); J: BCC (T06–7889) with mild-moderate
Fig. 3. Expression of MT-3 in primary normal human keratinocytes (NHEK) and Immortalized Human HaCaT Keratinocytes. HaCaT and NHEK cells were exposed to 1, 3, or
10 mM of the histone deacetylase inhibitor MS-275 for up to 72 h, or to 1 or 3 mM 5-azacytidine for 24 h. The post-conﬂuent control was held at conﬂuency for at least 72 h.
Messenger RNA levels for MT-3 were assessed using real-time PCR and gene speciﬁc primers on RNA isolated from cells in culture. Expression levels are expressed as
transcripts per 1000,000 transcripts of b-actin which was also assessed using real-time PCR. Signiﬁcant differences from control groups are designated as **p < 0.005,
***p < 0.0005 as determined by student’s unpaired t-test.
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The present study establishes that MT-3 is expressed in human
skin. The immunoreactivity for MT-3 was present in all viableFig. 4. Expression of MT-3 in normal human melanocytes (NHM). HEMa-LP cells
were exposed to 1, 3, or 1 mM of the histone deacetylase inhibitor MS-275 for up to
72 h, or to 1 or 3 mM 5-azacytidine for 24 h. The post-conﬂuent control was held at
conﬂuency for at least 72 h. Messenger RNA levels for MT-3 were assessed using
real-time PCR and gene speciﬁc primers on RNA isolated from cells in culture.
Expression levels are expressed as transcripts per 1000,000 transcripts of b-actin
which was also assessed using real-time PCR. Signiﬁcant differences from control
groups are designated as **p < 0.001, ***p < 0.0001 as determined by student’s
unpaired t-test.keratinocytes comprising the epidermis. The ﬁnding that MT-3 was
present in the epidermal keratinocytes has a potential impact on
the known association of arsenic exposure and the development of
skin disorders and related cancers. All members of the MT gene
family (MT-1, -2, -3 and -4) are known to bind heavy metals,
including As+3 (Vasak and Meloni, 2011; Irvine et al., 2013; Garla
et al., 2013). Previous studies employing a monoclonal antibody
against the E-9 epitope of the MT-1, -2, and -4 isoforms
demonstrated that these 3 isoforms are poorly expressed in
human skin and with expression restricted to the basal keratino-
cytes (Van den Oord and Delay, 1994; Karasawa et al., 1991;
Zamirska et al., 2012). The high sequence homology of these
3 isoforms prevents the generation of speciﬁc antibodies to the
individual isoforms. In contrast, the present study shows that a
large majority of keratinocytes in the epidermis of normal human
skin are moderately to strongly immunoreativity for MT-3. These
ﬁndings were consistent for 9 independent samples of human skin.
The antibody used for the localization of MT-3 is speciﬁc since it
was generated against the unique C-terminal amino acid sequence
that is present only in this MT isoform (Garrett et al.,1999). The fact
that human keratinocytes contain substantial levels of MT-3, and
that MT-3 can bind As+3, suggests a possible role for MT-3 in the
selective accumulation and sequestering of As+3 in skin. One
hypothesis to explain why skin is highly responsive to arsenic
exposure and cancer development is that skin localizes and store
As+3 due its high keratin content and the corresponding favorable
interaction with sulfhydryl groups (Kitchen, 2001; Lindgren et al.,
1982). The current ﬁnding suggests that MT-3 might play an
additive, or possibly larger, role in the ability of skin to sequester
and store As+3 in individuals chronically exposed to this metalloid.
Evidence to support the concept that MT expression in a normal
target tissue can elicit chronic effects can be found in the
nephropathy associated with chronic exposure to cadmium. The
MT-1 and MT-2 isoforms are predominantly expressed in the
proximal tubules of the human kidney, and this expression is
initiated during the early development of the kidney (Mididoddi
A. Slusser et al. / Toxicology Letters 232 (2015) 141–148 147et al., 1996). The MT-3 isoform is also expressed in the proximal
tubules and other tubular elements of the human kidney (Garrett
et al., 1999). The cortex of the human kidney has been shown to
accumulate cadmium, as a function of age, in humans without
occupational exposure (Satarug et al., 2002, 2010). Accumulation is
assumed to occur through cadmium's interaction with MT and
accumulation has been shown to reach a plateau at approximately
50 years of age. Despite the MT's being looked upon as having a
protective role against heavy metal toxicity in general, and the
proximal tubule in particular (Liu et al., 1995, 1998, 2000; Masters
et al., 1994), the fact remains that the kidney and the proximal
tubule is the cell type critically affected by chronic exposure to
cadmium (Andrews, 2000; Bernard et al., 1976; Bosco et al., 1986;
Gonich et al.,1980). It has been shown in human population studies
that even low exposure to cadmium alters renal tubule function
(Akesson et al., 2005). Thus, there is evidence in the kidney that
pre-existing expression of MT in the renal tubules both protects the
kidney from cadmium exposure, but this expression might also
render the organ susceptible to the chronic effects of the metal.
There is little evidence, either for or against, that would support a
similar role for MT-3 expression in human skin as regards the
chronic effects of exposure to arsenic.
The present study demonstrates that MT-3 is prominently
expressed in the majority of cells comprising the nevus, dysplastic
nevus, in situ melanoma, superﬁcial melanoma, and deeply
invasive melanoma. Although the sample set was relatively small,
there was no indication that expression was variable within or
between disease categories. A consequence of this pattern of
constant MT-3 expression is that the melanocytes, in all stages of
progression, are able to continue to bind and accumulate As+3 in an
environment where exposure to As+3 is at elevated levels.
Unfortunately, there is very little information in the literature
on conditions or mechanisms in vivo that would inﬂuence the
release of As+3 from MT-3 inside a cell or tissue. One could
speculate that if ultraviolet radiation inﬂuenced the release of As+3
from MT-3, it might impact on emerging research which suggests a
linkage between the development of melanoma and co-exposure
to As+3 and ultraviolet radiation (Cooper et al., 2014). The
expression of MT-1 and -2 has been examined in patients with
melanoma. It was shown that a gain of expression of MT-1 and -2 is
an adverse prognostic and survival factor for patients with this
cancer (Weinlick et al., 2003, 2006). In contrast to MT-3, MT-1 and
-2 is not expressed in the nevus and is gained later during the
development of the cancer.
The present study also shows that MT-3 is expressed in the
normal human epidermal keratinocytes that would give rise to
these cancers. The examination of these cancers show that all SCC
exhibit robust expression of MT-3, and that the majority of BCC
express MT-3 although a signiﬁcant proportion express mild levels
and some BCC failed to immunostain for this protein.
The results of the present study also show that cell cultures of
NHEK, HaCaT immortalized human keratinocytes, and normal
human melanocytes do not express MT-3 as would be unexpected
from their in situ patterns of MT-3 expression. This observation
shows that these cell lines are lacking a protein that can both bind
and sequester As+3 as well as serving as an antioxidant. The MT-
3 protein has also been shown to have growth inhibitory activity
outside the neural system(Gurel et al., 2003), be involved in necrotic
and apoptotic cell death (Somji et al., 2004, 2006) and in the
epithelial tomesenchymal transition(Kim et al., 2002; Bathula et al.,
2014). Exactly how this might impact on studies using these cell
lines to elucidate the mechanism/s of As+3 toxicity and carcinoge-
nicity is unknown, but may need to be considered in the
interpretationofpastandfuturestudies.ThelossofMT-3expression
in cell culturesderived fromtissues whereMT-3is expressedmaybe
a result of the cell culture environment. This is suggested by studieson MT-3 expression in bladder cancer and breast cancer cell lines.
This laboratory has shown that the epithelial cells of the human
bladder and breast do not express MT-3, but that the majority of
patient specimens of breast and bladder cancers do express MT-3
(Sens et al., 2000, 2001; Zhou et al., 2006; Somji et al., 2010). In
studies examining MT-3 expression in As+3 and Cd+2 transformed
bladder cancer cell lines and in MCF-7, T-47D, Hs 578 t, MDA-MB-
231 breast cancer cell lines it was demonstrated that none of the cell
lines expressed MT-3 (Zhou et al., 2006). However, when these cell
lines were transplanted into immune compromised mice, all the
resulting tumors showed prominent expression of MT-3. It has also
been shown that the expression of MT-3 mRNA could be induced
under cell culture conditions in the MT-3 non-expressing cell lines
following treatment with MS-273, a histone deacetylase inhibitor
(Somji et al., 2010, 2011). These results suggest that MT-3 is silenced
under cell culture conditions by a mechanism involving histone
acetylation.
Previous to the submission of this manuscript, no studies of MT-
3 expression in human skin or derived cancers existed in the
literature; however, recently a study was published during the
review process that documents the expression of MT-3 in human
skin, both in normal as well as BCC and SCC (Pula et al., 2014). The
ﬁndings of this study are in overall agreement with the above
ﬁndings with the exception that they have found higher levels of
MT-3 in SSC whereas the current study did not. Nevus, melanoma
and cultured cell models were not assessed in this study.
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